Mar 2, 2021 7:30 am EST SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
Feb 25, 2021 4:15 pm EST SCYNEXIS to Participate in Maxim Group’s Late Stage Innovations in Women’s Health Virtual Event
Feb 23, 2021 8:15 am EST SCYNEXIS and Amplity Health Announce Agreement to Support the Anticipated U.S. Commercialization of BrexafemmeTM (Ibrexafungerp) for Vaginal Yeast Infections
Feb 17, 2021 8:15 am EST SCYNEXIS Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Ibrexafungerp in Greater China
Dec 22, 2020 8:00 am EST SCYNEXIS Announces Closing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
Dec 17, 2020 9:28 am EST SCYNEXIS Announces Pricing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
Dec 16, 2020 4:21 pm EST SCYNEXIS Announces Launch of $50 Million Public Offering of Common Stock and Warrants
Dec 10, 2020 8:00 am EST SCYNEXIS Announces Advancement of Ibrexafungerp’s Intravenous Formulation to Clinical Stage and Provides Further Updates on its Clinical Studies in Patients with Life-Threatening Fungal Infections
Dec 7, 2020 8:00 am EST SCYNEXIS Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infections
